Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Fortress Biotech (FBIO) over the last 11 years, with Q3 2024 value amounting to -$1.4 million.

  • Fortress Biotech's Capital Expenditures fell 13960000.0% to -$1.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $28000.0, marking a year-over-year decrease of 7777.78%. This contributed to the annual value of $63000.0 for FY2023, which is 9767.96% down from last year.
  • Per Fortress Biotech's latest filing, its Capital Expenditures stood at -$1.4 million for Q3 2024, which was down 13960000.0% from $1.4 million recorded in Q2 2024.
  • In the past 5 years, Fortress Biotech's Capital Expenditures registered a high of $2.0 million during Q4 2021, and its lowest value of -$1.4 million during Q3 2024.
  • Moreover, its 5-year median value for Capital Expenditures was $500500.0 (2020), whereas its average is $515000.0.
  • Examining YoY changes over the last 5 years, Fortress Biotech's Capital Expenditures showed a top increase of 861875.0% in 2024 and a maximum decrease of 13960000.0% in 2024.
  • Over the past 5 years, Fortress Biotech's Capital Expenditures (Quarter) stood at $698000.0 in 2020, then skyrocketed by 180.37% to $2.0 million in 2021, then crashed by 95.35% to $91000.0 in 2022, then tumbled by 69.23% to $28000.0 in 2023, then plummeted by 5082.14% to -$1.4 million in 2024.
  • Its Capital Expenditures stands at -$1.4 million for Q3 2024, versus $1.4 million for Q2 2024 and $28000.0 for Q4 2023.